Balcom Alexandra, Chief Financial Officer, has filed 89 Form 4 transactions over the covered period, with a pronounced sell-side bias. The aggregate value of open-market sales reached $21.9 million, while no open-market purchases were recorded. The recent activity, spanning May through July 2026, is concentrated in Nuvalent (NUVL), with a cluster of sales on June 1 totaling roughly $1.1 million across eight separate transactions, and a further sale of approximately $1.4 million on July 1. These sales were paired with option exercises on the same dates—$114,450 and $37,095 on July 1, and $78,752 on June 1—consistent with a pattern of exercising and immediately selling shares.
The most recent filing, dated July 15, 2026, shows a different structure: a single transaction valued at $5.5 million coded as "U," which is not part of the standard legend and likely represents a conversion or other non-market event, alongside multiple "D" (sale back to issuer) entries and one "A" (grant) with zero reported value. Notably, the July 15 "D" transactions all carry a value of zero, suggesting they may be nominal or placeholder filings. The absence of any "P" (purchase) codes across the entire history underscores that Alexandra has not added shares through the open market during this window, instead consistently monetizing equity compensation.
Outside NUVL, a single "A" grant appears for Catalyst Biosciences (CBIO) on June 2, 2026, though with no dollar value attached. The overall direction is unambiguous: Alexandra has been a net seller, with the bulk of realized value coming from NUVL stock sales in the $20,000 to $1.4 million range. The recent 10 transactions include no buys, reinforcing a pattern of systematic liquidation rather than accumulation.
AI-assisted summary